

CURRICULUM VITAE: SONIA NAPRAVNIK

APRIL 2011

PERSONAL INFORMATION:

Name: Sonia Napravnik
Address: University of North Carolina at Chapel Hill
Department of Medicine, CB#7215
130 Mason Farm Rd, 2101 Bioinformatics Bldg
Chapel Hill, NC 27599-7215
Phone: 919-966-3875 (work), 919-216-8170 (pager)
Email: napravs@med.unc.edu

EDUCATION:

2000-2004 Doctor of Philosophy (Epidemiology)
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Dissertation Title: *Antiretroviral Therapy for HIV Infection in Puerto Rico, 1994 to 2000*

1998-2000 Master of Science in Public Health (Epidemiology)
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Thesis Title: *Detecting HIV Infection Among Pregnant Women: Considerations for Repeat Testing Among At Risk Populations*

1994-1998 Bachelor of Science (Nursing)
The University of Toronto, Toronto, Canada

1988-1992 Bachelor of Arts with Honors (Philosophy and History)
The University of Western Ontario, London, Canada

RESEARCH AND ACADEMIC POSITIONS:

2007-Present Research Assistant Professor, Gillings School of Global Public Health, Department of Epidemiology, The University of North Carolina at Chapel Hill

2006 Visiting Lecturer in Advanced Epidemiology and Biostatistics, College of Medicine, University of Malawi, Blantyre, Malawi

2005-Present Research Assistant Professor, School of Medicine, Division of Infectious Diseases, The University of North Carolina at Chapel Hill

2004-2005 Post-Doctoral Research Fellow, School of Medicine, Division of Infectious Diseases, The University of North Carolina at Chapel Hill

2004-Present Epidemiologist, Clinical Core, The University of North Carolina at Chapel Hill Center for AIDS Research

2002-Present Consultant, Retrovirus Research Center, School of Medicine, Universidad Central del Caribe, Bayamon, Puerto Rico

1999-2004 Graduate Research Assistant, School of Medicine, Division of Infectious Diseases, The University of North Carolina at Chapel Hill

1999 Summer Intern, Family Health International, Research Triangle Park, NC

1998-1999 Graduate Research Assistant, Gillings School of Global Public Health, Department of Epidemiology, The University of North Carolina at Chapel Hill

1996-1998 Research Assistant, School of Medicine, School of Nursing, Clarke Institute of Psychiatry, The University of Toronto, Toronto, Canada

ACADEMIC HONORS AND AWARDS:

2008	Clinical Infectious Diseases Award for Outstanding Review
2004	Delta Omega Public Health Honorary Society, UNC-CH
2004	Berton H. Kaplan Student Publication Award , UNC-CH
1998	Governor General's Academic Medals Program, Canada
1998	Gordon Cressy Student Leadership Award, University of Toronto, Canada
1998	M. Jean Wilson Scholarship, University of Toronto, Canada
1998	Marie Agnes Smith Scholarship, University of Toronto, Canada
1998	Mary Isobel Upson Trust, University of Toronto, Canada
1998	Sigma Theta Tau International Honor Society of Nursing, Canada
1997	Undergraduate Student Research Fellowship, University of Toronto, Canada
1997	Johnson and Johnson National Leadership Award, Canada
1997	Kathleen Russell Scholarship, University of Toronto, Canada
1997	Manuel and Anne Belle Pusitz Scholarship, University of Toronto, Canada
1996-1998	University of Toronto Scholar, University of Toronto, Canada

BIBLIOGRAPHY:**REFEREED PAPERS (* STUDENT OR FELLOW)**

1. Dennis AM, Napravnik S, Sena AC, Eron JJ. Late entry to HIV care among Latinos compared to non-Latinos in a Southeastern US cohort. *Clinical Infectious Diseases* 2011: In Press.
2. Edmonds A, Yotebieng M, Lusiana J, Matumona Y, Kitetele F, Napravnik S, Cole SR, Van Rie A, Behets F. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. *PLoS Medicine* 2011: In Press.
3. Brouwer ES, Napravnik S, Smiley SG, Corbett AH, Eron JJ. Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. *Pharmacoepidemiology and Drug Safety* 2011;20:432-439.
4. Stewart P, Cachafeiro A, Napravnik S, Eron JJ, Frank I, van der Horst C, Bosch RJ, Bettendorf D, Bohlin P, Fiscus SA. Performance characteristics of the Cavidix ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. *Journal of Clinical Virology* 2010;49:198-204.
5. Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC. CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have delayed presentation? *AIDS Research and Therapy* 2010;15:
6. McCoy SI, Jones B, Leone PA, Napravnik S, Quinlivan EB, Eron JJ, Miller WC. Variability in the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data. *Annals of Epidemiology* 2010;20:734-742.
7. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA, North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD). Virologic and immunologic response to HAART, by age and regimen class. *AIDS* 2010;24:2469-2479.
8. Althoff K, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RH, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert

- JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for HIV care in the United States and Canada. *Clinical Infectious Diseases* 2010;50:1512-1520.
9. Howe CJ, Cole SR, Napravnik S, Eron JJ Jr. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. *AIDS Research and Human Retroviruses* 2010;26:875-881.
 10. Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ Jr, Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. *American Journal of Epidemiology* 2010;171:198-205.
 11. Napravnik S, Cachafeiro A, Stewart P, Eron JJ Jr, Fiscus SA. HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. *Journal of Clinical Virology* 2010;47:19-22.
 12. Breban R, Napravnik S, Kahn J, Blower S. Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. *BMC Public Health* 2009;18(Suppl 1):S11-S20.
 13. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. *Clinical Infectious Diseases* 2009;49:1582-1590.
 14. Kitahata MM, Gange SJ, Abraham A, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD, for The North American AIDS Cohort Collaboration on Research and Design. Initiating rather than deferring HAART at a CD4+ count between 351-500 cells/mm³ is associated with improved survival. *New England Journal of Medicine* 2009;360:1815-1826.
 15. Edmonds A, Lusiana J, Napravnik S, Kitetele F, Van Rie A, Behets F. Antiretroviral therapy reduces incident tuberculosis among HIV-infected children. *International Journal of Epidemiology* 2009; 38: 1612-1621.
 16. Petersen ML, van der Lann MJ, Napravnik S, Eron JJ, Moore R, Deeks SG. Long term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. *AIDS* 2008;22:2097-2106.
 17. Wohl D, Waters D, Simpson R, Richard S, Schnell A, Napravnik S, , Keys J, Eron J, Hsue P. Ezetimibe alone reduces LDL-cholesterol among HIV-infected patients receiving combination antiretroviral therapy. *Clinical Infectious Disease* 2008;47:1105-1108.
 18. Pastakia SD, Corbett AH, Raasch RH, Napravnik S, Correll TA. Frequency of HIV-related medication errors and associated risk factors in hospitalized patients. *Ann Pharmacother* 2008;42:491-497.
 19. Murdoch DM, Napravnik S, Eron J Jr, Van Rie A. Smoking and predictors of pneumonia among HIV-infected patients receiving care in the HAART era. *The Open Respiratory Medicine Journal* 2008;2:22-28.
 20. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. *HIV Medicine* 2007;8:406-410.
 21. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-infected patients. *AIDS* 2007;21:825-834.
 22. Hosseinipour MC, Napravnik S, Joaki G, Gama S, Mbeye N, Banda B, Martinson F, Hoffman I, Cohen MS. HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi. *Journal of Infectious Diseases* 2007;195:1278-1282.

23. Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, Mofenson LM, Yogev R, McIntosh K, Pelton SI, Napravnik S, Stanley K, Nachman SA. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). *AIDS Research and Therapy* 2007;4:2.
24. Napravnik S, Eron JJ Jr, McKaig RG, Heine AD, Menezes P, Quinlivan EB. Access to HIV outpatient care in the Southeastern US. *AIDS Care* 2006;18:45-50.
25. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. Immunosuppression, hepatitis C infection and acute renal failure in HIV-infected patients. *Journal of Acquired Immune Deficiency Syndromes* 2006;42:368-372.
26. *Gay CL, Napravnik S, Eron JJ Jr. Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. *AIDS* 2006;20:775-778.
27. *Hooshyar D, Napravnik S, Eron JJ Jr. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. *AIDS* 2006;20:575-583.
28. Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, Danan E, Donovan K, Hossenipour M, Simpson RJ Jr. Randomized study of the safety and efficacy of fish oil (omega-3 Fatty Acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. *Clinical Infectious Diseases* 2005;41:1498-1504.
29. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. *Journal of Acquired Immune Deficiency Syndromes* 2005; 40:34-40.
30. Franceschini N, Napravnik S, Szczech LA, Eron Jr JJ, Finn W. Incidence and etiology of acute renal failure in ambulatory HIV patients. *Kidney International* 2005;67:1526-1531.
31. Whetten K, Reif S, Napravnik S, Swartz MS, Thielman NM, Eron JJ Jr., Soto T. Substance abuse and symptoms of mental illness among HIV positive persons in the southeast. *Southern Medical Journal* 2005;98:9-14.
32. Napravnik S, Poole C, Thomas JC, Eron Jr JJ. Gender Difference in HIV RNA levels: a meta-analysis of published studies. *Journal of Acquired Immune Deficiency Syndromes* 2002;31:11-19.
33. Napravnik S, Royce R, Walter E, Lim W. HIV-1 infected women and prenatal care utilization: Barriers and facilitators. *AIDS Patient Care and STDs* 2000;14:411-420.
34. Gallop R, Engels S, DiNunzio R, Napravnik S. Abused women's concerns about safety and the therapeutic environment. *Canadian Journal of Nursing Research* 1999; 31:53-70.

PRESENTATIONS AND PUBLISHED ABSTRACTS (* STUDENT OR FELLOW)

1. Edmonds A, Yotebieng M, Lusiana J, Matumona Y, Kitetele F, Napravnik S, Cole SR, Van Rie A, Behets F The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011 [Poster].
2. Dennis AM, Hue S, Hurt CB, Napravnik S, Pillay D, Eron JJ. Phylogenetic insight into HIV transmission networks in a Southeastern US Cohort. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011 [Presentation].
3. *Yanik EL, Napravnik S, Hurt CB, Dennis A, Kuruc JD, Eron JJ. Differences in prevalence of transmitted drug resistance mutations between acutely and chronically HIV-infected, antiretroviral naïve patients. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, Mexico, June 7-11, 2011 [Poster].
4. Brouwer ES, Napravnik S, Sturmer T, Brookhart MA, Simpson R, Floris-Moore M, Eron JJ. Utilization of an HIV clinical cohort study to validate coronary heart disease measurements

- ascertained from administrative data. 6th Annual Chapel Hill Drug Conference, Chapel Hill, North Carolina, May 11-12, 2011 [Poster]
5. Althoff K, Rebeiro P, Gill J, Horberg M, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S, and North American AIDS Cohort Collaboration on Research and Design. Trends in HIV viral load among adults in clinical care in the US and Canada, 1997-2007. 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 27-March 2, 2011 [Abstract 548].
 6. Justice A, Modur S, Tate J, Althoff K, Gange S, Gebo K, Kitahata M, Horberg M, Napravnik S, for the NA-ACCORD and VACS Project Teams. A prognostic index for those aging with HIV: extension of the VACS index to those on cART. 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 27-March 2, 2011 [Abstract 793].
 7. Hurt CB, Todd JV, Napravnik S, Moore RD, Eron JJ. Tolerability and hepatic safety of raltegravir among patients with HIV and viral hepatitis coinfection. 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 27-March 2, 2011 [Abstract 928].
 8. Golub ET, Deeks SG, Hunt PW, Martin JN, Zhang J, Horberg M, Gebo K, Kitahata M, Rachlis A, Greenblatt R, Saag M, Kirk G, Sterling S, Napravnik S, Moore R, Gange SJ, for the NA-ACCORD. Prevalence of extreme virologic and immunologic control in North American HIV treatment sites. 14th International Workshop on HIV Observational Databases, Barcelona, Spain, March 25-27, 2010 [Poster].
 9. Mugavero M, Napravnik S, Cole S, Eron J, Lau B, Crane H, Willig J, Kitahata M, Saag M, and the CFAR Network of Integrated Clinical Systems. Cumulative viral load burden and mortality among patients initiating antiretroviral therapy in the CNICS cohort. 14th International Workshop on HIV Observational Databases, Barcelona, Spain, March 25-27, 2010 [Presentation].
 10. *Arnoczy GS, Napravnik S, White BL, Juliano JJ, Peppercorn AF, Wohl DA, Eron JJ. Mortality in an HIV-infected clinical cohort in the Southeastern United States. 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania, October 29 - November 1, 2009 [Abstract 331].
 11. *Brouwer ES, Strayhorn L, Sena AC, Swygard H, Leone PA, Foust EM, Napravnik S, Eron JJ. A care bridge coordination program: linking HIV-infected patients with care in North Carolina. 137th American Public Health Association Annual Meeting, Philadelphia, Pennsylvania, November 7-11, 2009 [Presentation 5165].
 12. Napravnik S, Quinlivan EB, Brouwer ES, Leone PA, Foust EM, Cohen M, Swygard H, Sena AC, Gay C, Hightow-Weidman LB, Patterson KB, Eron JJ. Self-reported HIV testing delay in North Carolina. 137th American Public Health Association Annual Meeting, Philadelphia, Pennsylvania, November 7-11, 2009 [Abstract 3274].
 13. *Brouwer E, Napravnik S, Eron J. Predictors of nucleoside reverse transcriptase inhibitor use: channeling bias in HIV clinical care. 25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, Rhode Island, August 16-19, 2009 [Presentation 440]. Also available through *Pharmacoepidemiology Drug Safety* 2009; 18(S1).
 14. *Brouwer E, Napravnik S, Eron J. Influence of patient baseline clinical and demographic characteristics on choice of initial antiretroviral therapy regimen: evidence of channeling bias in HIV clinical care. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, July 19-22, 2009 [Abstract TUPEB117].
 15. Napravnik S, Brouwer ES, Quinlivan EB, Leone P, Foust E, Cohen M, Sena AC, Gay C, Hightow-Weidman L, Patterson KB, Swygard H, Eron JJ. Understanding delays in HIV care initiation in the Southeastern US. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, July 19-22, 2009 [Abstract CDB087].

16. *Mayo AJ, Napravnik S, Stalzer B, Quinlivan EB, Eron JJ. Sexually transmitted infection incidence relative to time since care entry in a longitudinal HIV clinical cohort. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, July 19-22, 2009 [Abstract MOPEB015].
17. *Woodruff A, Napravnik S, Brouwer ES, Stalzer B, Eron JJ. Childhood sexual abuse history affects HIV primary care utilization. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa, Sydney, Australia, July 19-22, 2009 [Abstract MOPED038].
18. Fiscus S, Cachafeiro A, Kshatriya R, Napravnik S, Owen M, Keating S, Busch M, Little S, Hogan C. Comparison of five HIV incidence assays with the less sensitive Vironostika HIV antibody assay for screening subjects for A5217. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009 [Abstract V-122].
19. Stewart P, Cachafeiro A, Napravnik S, Eron J, Frank I, van der Horst C, Bosch R, Bettendorf D, Bohlin P, Fiscus S. Performance of the Cavidix ExaVir Load Assay and the Ultra-sensitive p24 Antigen Assays Relative to the Roche Monitor HIV-1 RNA Assay: ACTG New Works Concept Sheet 227. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009 [Abstract V-121].
20. *Brouwer E, Napravnik S, Corbett A., Eron J. A validation study of self-reported antiretroviral use within a clinical cohort of HIV positive patients. 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Copenhagen, Denmark, August 17-20, 2008 [Oral Presentation]. Also available through Pharmacoepidemiology and Drug Safety 2008;17:S3.
21. Wohl D, Fleg A, Napravnik S, Williams M, Boyce R, Kiziah N, Harrell CA, White B. Virologic response to HAART among incarcerated HIV+ individuals. XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008 [Abstract THAB0503].
22. Swygard H, Torrone EA, Stalzer B, Napravnik S, Eron JJ. Sexual abuse associated with delayed entry into care and medical noncompliance among HIV positive women. XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008 [Abstract WEPE0815].
23. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. CD4+ T cell counts decline more slowly following initial virologic failure of highly active antiretroviral therapy when the failing regimen contains a protease inhibitor. 12th International Workshop on HIV Observational Databases, Malaga, Spain, March 27-30, 2008 [Presentation].
24. Fiscus S, Cachafeiro A, Napravnik S. The Cavidix ExaVir viral load and phenotype assays in comparison to HIV-1 RNA and genotyping assays. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008 [Paper 906].
25. Mugavero MJ, May M, Ribaldo HJ, Sterne JA, Napravnik S, Egger M, Saag MS, Gulick RM, ACTG, ART-CC. Outcomes of abacavir and efavirenz-based HAART: comparison of ACTG 5095 trial results with observational cohort studies. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008 [Paper 783].
26. Petersen M, van der Laan M, Napravnik S, Eron J, Moore R, Deeks S. Long-term consequences of the delay between virologic failure of HAART and regimen modification: a prospective cohort study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008 [Paper 798].
27. Napravnik S, Rublein J, Stalzer B, Eron J. Virologic response, immunologic reconstitution, and resistance evolution outcomes based on type of initial highly active antiretroviral therapy. 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney, Australia, July 22-25, 2007 [Abstract CDB244].

28. Menezes P, Atashili J, Napravnik S, Wohl D, Eron JJ. Effect of baseline body mass index on virologic response to initial highly active antiretroviral therapy among treatment naïve HIV positive persons in the Southeast United States. 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney, Australia, July 22-25, 2007 [Abstract WEPEB087].
29. Napravnik S, Brouwer ES, Keys J, Stalzer B, Eron JJ. Extensive HIV-1 antiretroviral drug class resistance is associated with inferior virological and clinical outcomes. XVI International HIV Drug Resistance Workshop, Barbados, June 12-16, 2007. [Abstract 59]. Also available through *Antiviral Therapy* 2007;12:S68.
30. Napravnik S, Rublein JC, Keys JR, Mikeal O, Eron JJ Jr. Effect of initial treatment with a non-nucleoside reverse transcriptase inhibitor versus a protease inhibitor on virologic response, immunologic reconstitution, and resistance evolution. 11th International Workshop on HIV Observational Databases, Monte Carlo, March 22-25, 2007 [Abstract 10C842].
31. *Keys JR, Napravnik S, Stalzer B, Mikeal O, Eron JJ Jr. HIV-1 variants with antiretroviral drug resistance mutations and remaining drug options among patients receiving HIV care. 11th International Workshop on HIV Observational Databases, Monte Carlo, March 22-25, 2007 [Abstract 10C844].
32. Wohl D, Hsue P, Richard S, Schnell A, Napravnik S, Simpson R, Keys J, Waters D. Ezetimibe's effects on the LDL cholesterol levels of HIV-infected patients receiving HAART. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007 [Paper 39].
33. *Brouwer ES, Napravnik S, Smith SR, Corbett AH, Eron JJ, Sherman S, Leone P. Access to the North Carolina AIDS drug assistance program. XVI International AIDS Conference, Toronto, Canada, August 13-18, 2006 [Abstract CDD1214].
34. *Pastakia S, Corbett A, Raasch R, Napravnik S, Correll T. Evaluation of the continuity of HIV care from the outpatient to inpatient setting. XVI International AIDS Conference, Toronto, Canada, August 13-18, 2006 [Abstract CDB1256].
35. Napravnik S, Keys J, Quinlivan EB, Wohl DA, Myers AM, Eron JJ Jr. Prevalence and predictors of triple-class antiretroviral drug resistance in routine HIV primary care. Clinical Implications of Resistance Session, XV International HIV Drug Resistance Workshop, Sitges, Spain, June 13-17, 2006. [Abstract 78]. Also available through *Antiviral Therapy* 2006;11:S88.
36. Fiscus S, Cachafeiro A, Stewart P, Napravnik S, Frank I, Eron JJ, and the AACTG NWCS 227 Team. Caviid exavir viral load and phenotype assays. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, December 16-19, 2006 [Paper 664].
37. Napravnik S, Mikeal O, McKaig RG, Matteson E, Menezes P, Eron JJ Jr. High risk for transmission of drug-resistant HIV variants among HIV-infected patients in routine clinical care. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005 [Abstract MoPp0203].
38. *Hooshyar D, Napravnik S, Miller W, Eron JJ Jr. Effect of hepatitis C co-infection on the durability of an initial highly active antiretroviral therapy regimen among HIV-infected patients. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005 [Abstract WePe12.9C17].
39. Franceschini N, Napravnik S, Eron JJ Jr., van der Horst C, Finn WF. Risk factors for developing acute renal failure among HIV-infected patients. 3rd World Congress of Nephrology, Singapore, June 26-30, 2005 [Abstract W-PO60008].
40. Hicks C, Eron J, Keiser P, Stout J, Frank I, Napravnik S, Giner J, Menezes P, Castellano C, Weidler J, Korich T, Bates M. HIV-1 replication capacity is an independent predictor of pre-treatment CD4

- lymphocyte count. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005. [Abstract 345]
41. Patterson K, Napravnik S, Eron J, Keruly SJ, Moore R. Age and sex effect on response to initial highly active antiretroviral therapy. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005. [Abstract 596]
 42. Edwards D, Stalzer B, Napravnik S, Stewart PW, Eron JJ Jr. HIV resistance evolution in the setting of stable antiretroviral therapy. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30 – November 2, 2004. [Abstract H-176]
 43. Franceschini N, Napravnik S, Szczech L, Menezes P, Finn W, Eron JJ Jr. Acute renal failure in HIV ambulatory patients. American Society of Nephrology Conference, St. Louis, Missouri, October 27 - November 1, 2004. [Abstract SU-PO215]
 44. Nkhoma J, Moses A, Zimba C, Mwale G, Murotho J, Dzinyemba W, Kamanga S, Jones D, Martinson FEA, Chilongozi D, Napravnik S, Hoffman IF, van der Horst C. Success with the use of rapid versus ELISA testing in the implementation of PMTCT programs. XV International AIDS Conference, Bangkok, July 11–16, 2004. [Abstract MoPeB3135]
 45. Napravnik S, Hooshyar D, van der Horst C, Quinlivan E, Menezes P, Greer J, Eron J Jr. Immunologic non-response among patients with virologic response in an antiretroviral naïve cohort initiating highly active antiretroviral therapy. XV International AIDS Conference, Bangkok, July 11–16, 2004. [Abstract MoPeB3135]
 46. Menezes P, Eron J, Napravnik S, Theodore D, Haley D, Ingle J, Quinlivan B, van der Horst C, Szczech L. Prevalence of Renal Disease in HIV positive patients. XV International AIDS Conference, Bangkok, July 11–16, 2004. [Abstract MoPeB3249]
 47. *Gay C, Napravnik S, Eron Jr JJ. Late presentation to care for HIV in the southeastern United States and associated risk factors. XV International AIDS Conference, Bangkok, July 11–16, 2004. [Abstract MoPeC3547]
 48. Napravnik S, McKaig R, Menezes P, Quinlivan E, Torok M, van der Horst C, Case M, Eron J Jr. Addressing research and clinical priorities in the era of HAART. 131st Annual Meeting of the American Public Health Association, San Francisco, November 15-19, 2003. [Abstract 3051]
 49. *Hooshyar D, Theodore D, Napravnik S, Robertson KR, Fried M, Eron JJ. Higher prevalence of active psychiatric diagnoses and substance abuse among patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infection. 41st Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 9 - 12, 2003. [Abstract 366-M]
 50. *Torok M, Napravnik S, Mckaig R, Menezes P, Eron J. Clinical Impact of the M184V mutation among HAART experienced patients on DDI. 2nd International AIDS Society Conference on Pathogenesis and Treatment, Paris, France, July 13-16, 2003. [Abstract 774]
 51. Patterson K, Napravnik S, Destro L, Menezes P, Eron J. Evolution of NNRTI mutations in a clinical setting. 2nd IAS Conference on Pathogenesis and Treatment, Paris, France, July 13-16, 2003. [Abstract 587]
 52. Napravnik S, McKaig RG, Menezes P, Haskins LM, Burge SS, Abernethy MG, van der Horst C, Eron JJ Jr. Prevalence and characteristics of HIV-infected individuals who engage in high risk sexual behavior. XIV International AIDS Conference, Barcelona, Spain, July 7 - 12, 2002. [Abstract WePeC6204]

53. Napravnik S, McKaig RG, Menezes P, Burge SS, Abernethy MG, Eron JJ. Predictors of entering primary HIV care at late stages of disease in the southeastern United States. XIV International AIDS Conference, Barcelona, Spain, July 7 - 12, 2002. [Abstract C10879]
54. McKaig RG, Napravnik S, Menezes P, Haskins LM, Burge SS, Eron JJ, et al. Prevalence and characteristics of HIV-infected individuals who engage in illicit substance abuse. XIV International AIDS Conference, Barcelona, Spain, July 7 - 12, 2002. [Abstract D11294]
55. Menezes P, Napravnik S, Miller WC, Eron JJ. Factors associated with normal CD4:CD8 ratios in HIV infected persons. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7 - 12, 2002. [Abstract WePeC6232]
56. Whetten-Goldstein K, Soto T, Napravnik S, Stevens R. Are mental health and substance abuse disorders truly a problem among HIV positive rural residents? 130th Annual American Public Health Association Meeting, Philadelphia, PA, November 9-13, 2002. [Abstract 45658]
57. Royce R, Napravnik S, Walter E, Girlando M, McDonald T. Trends in prenatal HIV counseling and testing from 1995 to 1998 in North Carolina. Second Conference for the Prevention of HIV Transmission from Mothers to Infants, Montreal, Quebec, September 1 - 5, 1999. [Abstract]
58. Royce R, Walter E, McAdams L, Eckman A, Napravnik S, Funk M. Availability of HIV serostatus during labor and delivery according to medical records. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Montreal, September 1 - 5, 1999. [Abstract]
59. Napravnik S, Connolly S, Alberti K, Kebbel C. Research utilization among undergraduate nursing students: An exploratory study. Conference on Research Utilization: Preparing for the New Millennium, Toronto, April 24 - 25, 1998. [Oral Presentation]
60. Gallop R, Napravnik S. Validation of the Sexual Abuse Comfort Scale. American Orthopsychiatry Association Conference, Toronto, March 12-15, 1997. [Abstract]

SCIENTIFIC JOURNAL PEER REVIEW:

AIDS

American Journal of Public Health

Antiviral Therapy

Canadian Medical Association Journal

Clinical Infectious Diseases

Health Promotion Practice

Journal of Antimicrobial Chemotherapy

Journal of Infectious Diseases

Journal of Women's Health

Sexually Transmitted Diseases

TEACHING EXPERIENCE

- 2009-Present Co-instructor for Quantitative Methods for Health Care Professionals (BIOS 541), The University of North Carolina at Chapel Hill
- 2009-Present Guest Lecturer for Design of Clinical Research Studies (EPID 690), The University of North Carolina at Chapel Hill
- 2008-Present Lecturer for HIV and Clinical Trials 101, Division of Infectious Diseases, The University of North Carolina at Chapel Hill
- 2006 Summer Lead Instructor for Advanced Epidemiology and Biostatistics, University of Malawi, School of Medicine, Lilongwe, Malawi
- 2004 Summer Lead Instructor for Clinical Epidemiology. 15th International Epidemiology Summer School in Ulm, Germany
- 2004 Spring Teaching Assistant for Theory and Quantitative Methods in Epidemiology (EPID 268). Department of Epidemiology, The University of North Carolina at Chapel Hill
- 2002 Fall Teaching Assistant for Epidemiologic Analysis of Binary Data (EPID 269). Department of Epidemiology, The University of North Carolina at Chapel Hill
- 2001 Spring Teaching Assistant for Quantitative Methods for Health Care Professionals II (BIOS 142). Department of Biostatistics, The University of North Carolina at Chapel Hill
- 2000 Fall Teaching Assistant for Quantitative Methods for Health Care Professionals I (BIOS 141). Department of Biostatistics, The University of North Carolina at Chapel Hill
- 2000 Spring Teaching Assistant for Foundations of Public Health Ethics (EPID 140). Department of Epidemiology, The University of North Carolina at Chapel Hill

STUDENT ADVISING**POST DOCTORAL FELLOW ADVISING**

- Victoria Mobley 2008-2013 K-24 National Institutes of Health
Mentoring junior faculty: the minority imperative
- Lisa Hightow-Weidman 2006-2011 K-23 National Institutes of Health
Internet-based HIV prevention for students at historically black colleges

DOCTORAL STUDENT ADVISING

- Elizabeth Yanik 2009-present PhD Epidemiology
Effects of antiretroviral therapy on risk of non-AIDS-defining cancers
- Sarah Radke 2008-present PhD Epidemiology (Chair: Napravnik)
Effect of hepatitis B co-infection on HIV antiretroviral therapy response and long-term outcomes
- Zhu Hao 2007-present PhD Epidemiology (Chair: Napravnik)
Antiretroviral therapy in China

DOCTORAL COMMITTEE MEMBERSHIP

- Petra Sander 2009-present PhD Epidemiology (Chair: Cole)
Alcohol and HIV seroconversion in men who have sex with men
- Andrew Edmonds 2009-2011 PhD Epidemiology (Chair: Behets)
Clinical progression and immunological effects of antiretroviral therapy in HIV-infected children: impacts of immunodeficiency and nutritional status

Emily Brouwer	2007-present	PhD Epidemiology (Chair: Sturmer) Cardiovascular outcomes of HIV antiretroviral therapy
Ella Nkhoma	2007-2009	PhD Epidemiology (Chair: Meshnick) Malaria and pregnancy outcomes in an area of high HIV and glucose-6-phosphate dehydrogenase deficiency prevalence
Jessica R. Keys	2005-present	PhD Epidemiology (Chair: Poole) Minority HIV-1 resistance mutations

MASTERS ADVISEES

Sarah Radke	2008-2009	MSPH Epidemiology Provision of hepatitis B vaccine in the UNC HIV outpatient clinic
Ashley Mayo	2007-2008	MSPH Epidemiology Incident sexually transmitted infections and time since entry to HIV care
Andrew Edmonds	2006-2007	MSPH Epidemiology HIV, tuberculosis and antiretroviral therapy
David M. Murdoch	2005-2006	MPH Epidemiology Smoking increases risk of pneumonia among HIV-seropositive patients in the Southeastern United States in the HAART era
Dina Hooshyar	2004-2005	MPH Epidemiology Effect of hepatitis C co-infection on the durability of an initial highly active antiretroviral therapy regimen among HIV-infected patients
Jessica R. Keys	2004-2005	MSPH Epidemiology Identifying predictors of multi-drug resistant HIV-1 in a cohort of patients with clinically implicated genotype assays
Vidyunmala Seksaria	2004-2005	MPH Epidemiology Hepatitis C virus co-infection and provision of antiretroviral therapy?
Nasreen S. Jessani	2003-2004	MPH Health Policy and Administration HIV serostatus disclosure and antiretroviral therapy adherence

ONGOING SPONSORED RESEARCH PROJECTS**FEDERAL**

- R01 HS018731 (Napravnik, PI) 04/01/10-03/31/13
 AHRQ \$391,524 (Direct-current year)
Comparative safety of antiretrovirals among HIV-infected patients: minimizing coronary heart disease outcomes
 This study will directly influence the clinical care of HIV-infected patients and contribute to existing comparative effectiveness research methods by employing novel and innovative calibration techniques to account for unmeasured confounding in administrative claims data relying on data available through other sources.
 Role: Principal Investigator
- R21 AI087360 (Mugavero, PI, University of Alabama at Birmingham) 06/01/10-05/31/12
 NIH/NIAID \$166,685 (Direct-current year)
Viremia copy-years: measuring the effect of cumulative HIV burden on outcomes
 This study will develop a novel epidemiologic measure of cumulative plasma HIV RNA (viral load) burden among treatment-naïve patients initiating ART in CNICS. The independent prognostic value of this area under the curve viral load measure, viremia copy-years, in predicting all-cause mortality will be evaluated along with patient-level factors associated with greater cumulative viral burden following ART initiation.
 Role: Investigator (UNC Principal Investigator)
- U01 AI069918 (Moore , PI, Johns Hopkins University) 04/01/06-03/31/16
 NIH/NIAID \$855,069 (Direct-current year)
North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)
 The NA-ACCORD is an international collaboration of classical epidemiologic and observational clinical HIV cohorts. The overall aims are to study HIV treatment outcomes and develop new methods for observational HIV research.
 Role: Investigator (UNC Principal Investigator)
- U01 AI069918 (Moore, PI, Johns Hopkins University) 09/22/09-08/31/11
 NIH/NIAID \$3,656,031 (Direct)
North American AIDS Cohorts Collaboration on Research and Design – ARRA Supplement
 The NA-ACCORD is an international collaboration of classical epidemiologic and observational clinical HIV cohorts. The overall aims are to study HIV treatment outcomes and develop new methods for observational HIV research.
 Role: Investigator (UNC Principal Investigator)
- R24 AI067039 (Saag , PI, University of Alabama) 09/01/08-08/31/11
 NIH/NIAID \$2,978,000 (Direct-current yr)
CFAR Network of Integrated Clinical Systems (CNICS)
 The CNICS is a collaboration of NIH Center for AIDS Research HIV Clinical Cohorts with the overall objective to improve the clinical management and outcomes of HIV-infected individuals receiving primary HIV care.
 Role: Investigator
- R24 AI067039 (Saag , PI, University of Alabama) 09/22/09-08/31/11
 NIH/NIAID \$912,895 (Direct)
CFAR Network of Integrated Clinical Systems (CNICS) – ARRA Supplement

The CNICS is a collaboration of NIH Center for AIDS Research HIV Clinical Cohorts with the overall objective to improve the clinical management and outcomes of HIV-infected individuals receiving primary HIV care.

Role: Investigator

R01 DA030793 (Wohl, PI) 09/30/10-09/29/15
NIH/NIAID \$1,462,001 (Direct-current yr)

RCT of an augmented test, treat, link & retain model for NC and Texas prisoners

To develop, implement and test a novel intervention to maintain antiretroviral-mediated suppression of HIV replication following prison release for HIV transmission prevention. HIV-infected inmates in NC and TX will be enrolled in this randomized clinical trial.

Role: Investigator

P30 AI590410 (Swanstrom, PI) 08/15/06-05/31/16
NIH/NIAID \$1,732,719 (Direct-current yr)

Center for AIDS Research (CFAR)

The main goals of the core are to facilitate and coordinate HIV translational research for basic scientists and clinical investigators. The Clinical Core promotes the development of new areas of HIV research by supporting new and experienced investigators.

Role: Epidemiologist

U01 (Kashuba, PI) 03/01/11 – 02/28/14
NIH/NIAID \$498,231 (Direct-current year)

NIAID Clinical trial implementation cooperative agreement (U01)

The main goal is to develop a model for oral antiretroviral (ARV) prevention strategies. The project will determine how 4 selected ARVs concentrate in 3 mucosal surfaces at risk for HIV infection. In tissue culture, ARV concentrations that protect tissues from HIV infection under multiple conditions will be identified. We will combine the aforementioned data in a mathematical model that will identify the most protective drug regimen to investigate in further clinical studies.

Role: Investigator

R34 AI087065 (Kashuba, PI) 12/15/09-05/30/11
NIH/NIAID \$75,000 (Direct-current year)

Preventing HIV infection in women: targeting antiretrovirals to mucosal tissues

The main goal of this project is to identify which antiretrovirals and which dosing regimens are superior for preventing HIV infection in women.

Role: Investigator

NON-FEDERAL

Clinical Outcomes of Second-line ART (Eron, PI) 07/29/10 – 03/31/13
Bristol Myers Squibb, Inc \$150,000 (Direct)

Role: Investigator

Incidence of targeted events among HIV-infected patients (Eron, PI) 11/01/07 – 12/31/12
Pfizer, Inc \$250,000 (Direct)

Role: Investigator

Efficacy and tolerability of raltegravir (Hurt, PI) 09/05/08 – 09/04/11
Merck and Co., Inc \$100,700 (Direct)

Role: Investigator

COMPLETED SPONSORED RESEARCH PROJECTS

NC TraCS Large Pilot Award (Napravnik, PI) NC Translational and Clinical Sciences Institute <i>Investigation of Cardiovascular Disease Outcomes Among Patients with HIV</i> Role: Principal Investigator	05/01/09 – 07/31/10 \$49,807 (Direct)
Investments for the Future Award (Eron, PI) UNC School of Medicine <i>Integrated Response to HIV/AIDS Prevention and Treatment</i> Role: Investigator	07/01/07 – 06/30/10 \$805,000 (Direct)
(08-0988) <i>Continuous Quality Improvement in HIV Care</i> (Napravnik, PI) NC Dept of Health and Human Services Role: Principal Investigator	07/01/07 – 03/31/08 \$591,240 (Direct)
(06-051227) <i>Effect of type of initial HAART</i> (Eron, PI) Abbott Virology Role: Investigator	01/01/06 – 12/31/08 \$75,000 (Direct)